Close
Help
Need Help?





JOURNAL

Clinical Medicine Reviews in Therapeutics

272,056 Journal Article Views | Journal Analytics

Golimumab-A Review of its Therapeutic Efficacy in Rheumatoid Arthritis

Submit a Paper



Publication Date: 12 Jul 2010

Type: Review

Journal: Clinical Medicine Reviews in Therapeutics

Citation: Clinical Medicine Reviews in Therapeutics 2010:2

doi: 10.4137/CMRT.S4775

Abstract

The advent of monoclonal antibodies to Tumor necrosis factor-α (TNF), has revolutionized the treatment in rheumatoid arthritis (RA). These agents have proved to be highly efficacious, making remission an achievable goal in RA. Golimumab is a human monoclonal antibody to TNF, which is approved by the US FDA for the treatment of RA, psoriatic arthritis and ankylosing spondylitis since April 2009. Golimumab is a useful addition to the therapeutic armamentarium against rheumatoid arthritis. It has proven efficacy in RA patients with active disease, despite treatment with methotrexate and also found to be useful in patients who have failed on a prior anti-TNF agent. It offers a reasonable alternative to other anti-TNF drugs like infliximab, adalimumab or etanercept. The short-term safety profile, based on short-term RCTs, is reasonable with no differences in total adverse events, serious infections, cancer, tuberculosis or deaths. However, Long-term surveillance studies are needed for safety assessment.


Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)






What Your Colleagues Say About Libertas Academica
This is the first time I have published in Genetics and Epigenetics and it was easy and efficient. The peer reviews took less time than I supposed they would.  The remarks were appropriate and made by qualified peer reviewers. All paths from submission to publication were easy, rapid and understandable. I was impressed by the professionalism and punctuality of peer reviewers, Editor in Chief and all staff members of this journal.  Keep up the good ...
Professor Danuta Zastavna (Institute of Hereditary Pathology, Lviv, Ukraine)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results